Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Austin, Texas

Austin, Texas, April 8, 2015 – Vince Young and his teammates from the 2005 National Championship Team including Kasey Studdard and Ahmad Brooks will host the sixth annual Champions to CureDuchenne Austin Texas-sized Tailgate Party on April 11 at The University of Texas Golf Club to raise money to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy.

“I’m glad to host the Champions to CureDuchenne event again this year to help save the lives of boys with Duchenne,” said Young, former NFL football player and University of Texas quarterback, who was motivated to help after meeting 10-year-old Timothy Revell and his 7-year-old brother Andrew who both live with Duchenne. “I can’t imagine what it would be like to not be able to use my muscles. Boys this age should be able run, play sports and not have to worry about their muscles getting weaker. We need to find a cure to save Timothy, Andrew and others with Duchenne.”

Tim and Laura Revell created the Champions to CureDuchenne event to help raise awareness and fund research to find a cure for their sons and the other 300,000 worldwide with Duchenne.  Revell has also run the Austin Marathon for the past 10 years to raise money for the cause.

“When our sons were diagnosed there was little hope for boys with Duchenne muscular dystrophy,” said Tim Revell.  “It’s devastating to know your two children, your legacy, won’t out live you. This generation of Duchenne boys could be the first to thrive and survive this devastating disease. The Austin community has an opportunity to be part of the solution. We just need to continue to fund research until there is cure for all boys with Duchenne.”

Duchenne is a progressive muscle-wasting disease that impacts one in 3,500 boys. Boys with Duchenne are usually diagnosed before the age of 5, in a wheelchair by 12 and most don’t survive their mid-20s. Currently, there is no approved treatment for Duchenne.  All proceeds of the Champions to CureDuchenne Austin event will fund a Duchenne research project led by Dr. Kevin Flanigan from Nationwide Children’s Hospital.       

The Champions to CureDuchenne Austin event is presented by Johnny Carino’s. Event sponsors include HEB, Cullen Family Charitable Foundation, Revenew International LLC, NFL Alumni Austin, The Page Foundation, Summit Stoneworks, Arthur J. Gallagher & Co., and Audio-Visual Consultations. 

The event will feature food, drinks, entertainment and a live and silent auction.  The cost is $150 per person.  For tickets and more information, please go to www.ChampionsforaCure.org.

Seven CureDuchenne-funded research projects have advanced into human clinical trials, providing a ray of hope for Duchenne families around the world. CureDuchenne funded early research in three companies, Prosensa (recently acquired by BioMarin), Sarepta Therapeutics and PTC Therapeutics, each of these biotech companies will be applying for FDA approval for their Duchenne drugs this year. These drugs could be the first therapies ever approved for this deadly disease.

Follow us on Facebook, Twitter and YouTube.

About CureDuchenne
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have advanced into human clinical trials – a unique accomplishment, as few health-related nonprofits have been as successful in being a catalyst for human clinical trials.

 

###